Table 1.
Primary and laboratory isolates of HIV-1 used in the infection experiments: Patients and characteristics of the isolates
| Patient | CD4 count,* cells/mm3 | Virus isolate | Virus phenotype† | p24 core antigen,‡ ng/ml |
|---|---|---|---|---|
| A | 400 | DS pbmc CD8- | SI | 150 |
| B | 354 | OR pbmc CD8- | SI | 262 |
| C | 79 | 5774 PBMC | SI | 68 |
| D | — | G3 | NSI | 120 |
| E | 923 | OT pbmc CD8- | SI | 110 |
| F | 411 | P001 pbmc CD8- | SI | 24 |
| G | 386 | L002 PBMC | SI | 336 |
| H | — | 22069-05 | SI | 312 |
| J | — | JV 1083 | NSI | 16 |
| K | — | 571 | SI | 170 |
| — | — | IIIB | SI | 237 |
| — | — | BaL | NSI | 688 |
Primary virus isolates from 10 patients, as well as two laboratory-adapted model isolates, tested on CD4-positive mouse fibroblasts (NIH 3T3) expressing various types of human chemotactic receptors. Primary isolates were grown by coculturing with stimulated human PBMC (in the four isolates designed “pbmc CD8-,” PBMC were depleted of CD8-positive cells by using DynaBeads). G3 and JV 1083 are primary isolates from Nigerian clade G/A. HIV-1 BaL was passaged several times exclusively in primary adherent macrophage cultures derived from peripheral blood. HIV-1 IIIB is a long-term, laboratory-passed isolate grown in H9 cells.
Absolute counts of CD4-positive lymphocytes in patients were measured at the time of initial blood draw.
Phenotype was classified in MT-2 assays after the infection.
Viral titers were evaluated in vitro by using p24 core antigen ELISA.